Lapinski, Robert Flisiak 4:15 PM 36: Nucleoside Analogs Prevent Disease Progression in HBV-Related Acute-on-Chronic Liver Failure: Validation of the TPPM Model Ke Ma, Junshuai Wang, Meifang Han, Wei Guo, Jiaquan Huang, Daofeng Yang, Xiping Zhao, Jianxin Song, Deying Tian, Junying Qi, Yuancheng Huang, Qin Ning Parallel 5: HCV Therapeutics: Real World Experience Sunday, November 3 3:00 – 4:30 PM Hall E/General Session MODERATORS: Richard K. Sterling, MD, MSc Stevan A. Gonzalez, MD 3:00 PM 37: Antiviral Treatment for Hepatitis C Virus in HIV/HCV Co-infected
Patients George N. Ioannou, John D. Scott, Yin Yang, Pamela Green, Lauren A. Beste 3:15 PM 38: Telaprevir combination therapy in treatment-naïve and experienced Ixazomib nmr patients co-infected with HCV and HIV Marisa Montes, Mark Nelson, Marie Girard, Joe Sasadeusz, Andrzej Horban, Beatriz Grinsztejn, Natalia Zakharova, Karolin Falconer, Inge Dierynck, Donghan Luo, Yi-Wen high throughput screening compounds Ma, James Witek 3:30 PM 39: Differential Impact of Type 1 Interferon on Chronic Hepatitis C Infection in HIV Co-infection, Pre- and Post- HAART Ashwin Balagopal, Abraham J. Kandathil, Johnanathan Wood, Fuat Kurbanov, Jeffrey Quinn, Justin Richer, Yvonne M. Higgins,
Lois Eldred, Zhiping Li, Mark S. Sulkowski, David L. Thomas 3:45 PM 40: Telaprevir in the Treatment of Acute HCV Infection in HIV-infected Men: SVR 12 Results Daniel S. Fierer, Douglas T. Dieterich, Michael P. Mullen, Andrea D. Branch, Alison J. Uriel, Damaris C. Carriero, Wouter O. van Seggelen, Rosanne M. Hijdra, David Cassagnol 4:00 PM 41:Virologic Outcomes and Adherence MCE公司 to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR) in the United States (HCV-TARGET) Adrian M. Di Bisceglie, Alexander Kuo, Vinod K. Rustgi, Mark S. Sulkowski, Richard K. Sterling, Thomas Stewart, Michael W. Fried, Jonathan M. Fenkel, Hisham ElGenaidi, Mitchell A. Mah’moud, George M. Abraham 4:15 PM 42: Serious Adverse Drug Reactions Related to Boceprevir:
Analysis of Food and Drug Administration Reported Events Bryan L. Love, Vishvas Garg, Rasha Arabyat, Dennis W. Raisch, Charles L. Bennett Parallel 6: Living Donors Transplantation and Hepatic Resection Sunday, November 3 3:00 – 4:30 PM Room 152A MODERATORS: James Trotter, MD Elizabeth A. Pomfret, MD, PhD 3:00 PM 43: Pain Management in Living Liver Donors Daniela Ladner, Robert A. Fisher, Elizabeth A. Pomfret, Mary Ann Simpson, Robert S. Brown, Amna Daud, Kathryn Waitzman, John R. Joseph, Donna Woods 3:15 PM 44: Activation of the Constitutive Androstane Receptor (CAR) reverses deficient liver regeneration in the Small-For-Size Syndrome via Foxm1b and miR375/YAP-dependent pathways Christoph Tschuor, Ekaterina Kachaylo, Perparim Limani, Amedeo Columbano, Andrea Schlegel, Jae Hwi Jang, Dimitri A.